Novartis Venture joins Forendo series A

Forendo Pharma of Finland has raised €12m in a series A financing round. Novartis Venture Fund and Merck Serono (MS) Ventures invested, along with current shareholders Karolinska Development, Novo Seeds and Finnvera.

More from Immunological

More from Therapy Areas